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A b s t r a c t  
This study was designated to form core-enriched 5-flourouracil (5-FU) niosomes and apply it to skin 
as a niosomal gel for topical treatment of skin cancer. Different molar ratios of the two surfactants 
used namely; sorbitan monostearate (Span 60), sorbitan monolaurate (Span 20) to cholesterol were 
employed, in addition; sodium deoxycholate was used a co-surfactant. The drug was successfully 
entrapped in niosomes with entrapment efficiency reached up to 67.08 ± 2.53 mg % (w/w). The 
produced niosomes had particle size below 300 nm, zeta potential values between -15 ± -1.6 and -
37.73 ± -2.53 mV and polydispersity index between 0.09 ± 0.06 and 0.20 ± 0.02. Transmission 
electron microscopy showed the formation of spherical niosomes with closed bilayer structure. 
Formula N8 had more than two fold increase in amount permeated compared to free drug in in-vitro 
permeation study. The niosomal gel formulae had better permeation parameters compared to 
formulae containing free drug. Niosomal gel formula composed of sodium carboxymethyle cellulose 
(Na CMC) had the best permeation parameters among the produced gel formulae. Histopathological 
studies showed that niosomal 5-FU gel was able to penetrate more readily into deep layers of skin to 
treat tumor as indicated by the reduction in inflammatory reaction and hemorrhage signs observed in 
animals treated by niosomal 5-FU gel.  
Keywords: 5-Flourouracil, niosomal gel, skin cancer, transdermal permeation, niosomes. 
Introduction 
Chemotherapy is one of the main therapeutic strategies for 
treatment of cancer in addition to surgery, radiation and biologic 
therapies (immunotherapy and hormonal therapy) [1]). Cytotoxic 
drugs are the most frequently used chemotherapeutic agents for 
cancer treatment. The main action of cytotoxic drugs is to destroy 
cells that are rapidly growing and dividing such as cancer cells. 
Consequently; cancer cells are the most preferentially killed cells 
by cytotoxic agents [2]. However; treatment failure following 
administration of these drugs is still encountered and the clinical 
results are frequently less than desired.  
5-Fluorouracil is a hydrophilic anticancer drug that is used in 
management of many types of skin cancer. A 1% solution of 5-FU 
in water has a pH of 4.5 to 5.0 [3, 4]. The mechanism of action of 5-
FU involves the interference with nucleoside metabolism and 
incorporation into RNA and DNA, eventually resulting in cell death.  
Actually; this drug has a reasonable anti-cancer activity against 
lesions related to squamous cell carcinoma such as Bowen’s 
disease [5].   
Due to its hydrophilic and acidic nature, the permeation of 5-FU 
across the lipophilic layers of the skin is found to be very low. 
Additionally, 5-FU is metabolized with high rate in the body, so; to 
maintain a reasonable therapeutic concentration , high doses of the 
drug will be administered, which could induce great toxic effects [6, 
7]. For these reasons; many researchers investigated other 
techniques to enhance its transdermal permeation. These 
techniques included; use of permeation enhancers, iontophoresis 
[8], laser treatment [9], prodrug technique [10] and many others 
[11]. Development of resistance by cancer cells against 5-FU had 
decreased the clinical use of 5-FU over the past 50 years. For 
example; it was reported that the use of 5-FU alone in treating 
colorectal cancer resulted in only 10 % response [3].  
These disadvantages and other toxic side effects of 5-FU could be 
decreased by specifically delivering such drug into cancer cells and 
minimizing the exposure of other healthy cells to this agent 
Niosomes are known to be vesicular systems formed by the self-
assembly of non-ionic surfactants in aqueous media to form closed 
bilayer structures. Such assembly [12] frequently requires some 
energy like physical agitation or heating. Those vesicular delivery 
systems can provide a way to deliver active agents such as 5-FU 
into the required target site due to their desirable prosperities such 
as their ability to entrap hydrophilic drugs such as 5-FU into their 
core and their ability to pass readily through lipophilic membranes 
and finally their ability to act as penetration enhancers. 
The aim of work of this study is to formulate 5-FU in the form of 
niosomal gel in order to enhance its anticancer activity through 
improving its transdermal permeation and help its delivery more 
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 5-FU powder was purchased from Merck Co. (Germany). 
Cholesterol, sorbitan monostearate (Span 60), sorbitan 
monolaurate (Span 20), sodium deoxycholate, Phosphate Buffer 
Saline tablets (PBS) and dialysis bags with a molecular weight cut 
off of 12000kDa were purchased from Sigma Aldrich (USA). 
Cellulose nitrate papers with pore size 0.2 µm were purchased from 
Seitz Co. (Germany). Absolute ethanol, chloroform and Sӧrensen’s 
Phosphat Buffer, composed of sodium chloride, di-sodium 
hydrogen orthophosphate and potassium-dihydrogen 
orthophosphate were purchased from Elgomhoria CO. (Egypt). 
Sodium carboxymethyle cellulose (Na CMC), 
hydroxypropylemethyle cellulose (HPMC), chitosan and 
Hematoxylin and eosin stains were purchased from Sigma Aldrich 
(USA). All other chemicals and solvents used were of HPLC grade. 
 
Preparation of 5-FU loaded niosomes 
 
5-FU niosomes were prepared with thin film-hydration technique 
[13]. Briefly; the required quantities of the surfactant (Span20 or 
Span60) and cholesterol in different molar ratios (1:2 and 1:3) of  
cholesterol to Span respectively, with or without 0.5 % w/w of the 
co-surfactant Na deoxycholate (Table 1) were dissolved in 5mL of  
a solvent mixture (2:1, v/v of  chloroform: methanol respectively) in 
a round-bottom flask. The organic solvents were evaporated using 
a rotary evaporator (Stuart rotary evaporator (RE300, UK)) at 40◦C 
for 10 min under vacuum using vacuum pump (Stuart vacuum 
pump (RE3022C, UK)) to form a thin film on the wall of the flask; 
the last traces of organic solvents were removed by desiccation 
under vacuum for 2 h. thin film was hydrated using 10mL of 
phosphate buffer (pH 7.4) at 55◦C. The resulting niosomal 
suspension was sonicated in a bath sonicator (Ney ultra sonic 
cleaner (57 H, USA)) for one hour to obtain multilamellar niosomes. 
 




Drug (mg) Molar ratio of 
cholesterol: 
surfactant 




N1 10 1:2 45 Span60 100 absent 
N2 10 45 Span60 100 present 
N3 10 1:3 45 Span60 150 absent 
N4 10 45 Span60 150 present 
N5 10 1:2 55 Span20 100 absent 
N6 10 55 Span20 100 present 
N7 10 1:3 55 Span20 150 absent 
N8 10 55 Span20 150 present 
 
Characterization of 5-FU loaded niosomes 
 
Determination of entrapment efficiency 
 
Drug entrapped into niosomes was separated from free 5-FU by 
centrifugation of the niosomal suspension at 50000 rpm for one 
hour (Beckman ultra centrifuge, (GS, 6KR USA)), washed twice 
and finally recenrifuged to ensure complete removal of the 
unentrapped 5-FU. The amount of encapsulated 5-FU was 
determined by lysis of the separated vesicles using 93% ethanol, 
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heating to 60oC, cooling the solution to room temperature then 
centrifugation of the solution at 4000 rpm for 30 min. Finally 1ml of 
the supernatant was diluted to 10 ml using PBS (pH 7.4) and 
measured spectrophotometrically at λmax 266 nm (Jasco 
spectrophotometer (V530, USA)).  
The 5-FU entrapment efficiency was determined using equation (1) 
 
5-FU entrapment efficiency= Amount of drug entrapped  X 100   (1) 
                                                Total amount of drug added 
 
Zeta potential and size measurement 
 
Zeta potential, particle sizes and polydispersity index were 
determined by diluting 5-FU niosomal suspension by distilled water.  
The particles size was measured using Malvern PCS4700 system, 
while zeta potential of nanosuspension samples was determined by 
using Zetasizer 2000. 
 
Transmission electron microscopy 
 
Morphological characters of 5-FU loaded niosomes were illustrated 
using transmission electron microscopy (Transmission electron 
microscope analyzer (Jeol, Japan)). The device was operating at 
an accelerating voltage of 80 kV.  A drop of niosome suspensions 
was applied onto a cupper grid, stained with urinyle acetate, left to 
dry and finally examined. 
 
In-vitro diffusion study   
 
Diffusion study was done using different volumes of niosomal 
suspension carrying fixed weights of 5-FU ( 2 mg) that were 
inserted into tube (surface area 5 cm2) after sealing one its lower 
surface with cellulose nitrate paper ( pore size of 0.2µm)  which 
was immersed in isopropyl myristate overnight to simulate the 
lipophilic characters of the stratum corneum  [14]. The tubes was 
suspended in PBS (25 ml, pH 7.4) at 37±0.5oC and considered as 
a receptor chamber. The receptor was stirred at 100 rpm on a 
magnetic stirrer.  Aliquots of one ml were withdrawn from receptor 
chamber at predetermined time intervals and diluted to 1:10. The 
receptor chamber was compensated with equal volumes of fresh 
medium. The withdrawn samples were filtered through 0.45 µm 
pore filter and finally measured at λmax  266 nm.  
The permeation data of 5-FU was graphically plotted as the 
cumulative amount of drug permeated per unit area as a function of 
time. The permeation profiles provided permeation parameters 
namely; the permeability coefficient (Kp) ( i.e. the slope of the 
straight line portion of the curve divided by concentration of drug 
originally added), lag time (i.e. the X-intercept of the linear portion 
of the graph) and Q24 (i.e. the cumulative amount of the drug 
permeated per unit area after 24 hours).  
Based on the obtained results from the previous tests, formula N8 
was chosen to be incorporated in three different gel matrices. 
Anionic, neutral and cationic Bases namely; Na CMC (3% w/v), 
(HPMC (2% w/v) and chitosan (1.5%) were used. These matrices 
were mixed with certain volume of N8 which contained a fixed 
amount of 5-FU so that the final concentration of drug in the gel 
was 20 % w/w.  They were left to equilibrate in the refrigerator for 
24 hours before use. In The diffusion experiment of the gel, about 
0.05 mL of the gel containing 2.5 mg of 5-FU was inserted in the 
donor chamber and the experiment was carried out in a way similar 




The stability of vesicles was tested by measuring the encapsulation 






BALB/c mice with average weight of 18 ± 2 gm were used.  
 
Induction of tumor 
 
The mice were divided into three groups each composed of six 
animals. Each animal was injected in the right thigh subcutaneously 
with 0.2 ml 1x 106 single cell suspension isolated from Ehrlich 
ascetics’ carcinoma (EAC). The parent line of Ehrlich ascetics’ 
carcinoma was supplied by the National cancer Institute of Cairo 
University. Animals were housed at the same temperature and 
humidity and received similar diet regimen. Animals were left for 10 
days to allow tumor growth, the hair covering the right thigh was 
removed using electric hair clipper. Animals were divided into three 
groups namely; group A that served as negative control (received 
no drug or external treatment), group B that served as positive 
control and received free 5-FU topical gel twice daily and group C 
that Received 5-FU loaded niosome topical gel twice daily. The 
dose was calculated according to Paget and Barns to be equivalent 
to that used for humans (i.e. 2.27 mg /ml for animal) [15]. Each 
animal was put in separate cage and subjected to the treatment 
with the formula meant for each group. All mice were under 




14 days after tumor implantation part of the mice from group A 
were sacrificed and biopsies were performed. The tumors that 
developed at the site of injection of EAC cells were excised and 
fixed in 10% formaldehyde. The preserved tumor tissue was 
dehydrated, cleared, and processed for routine paraffin-block 
preparation using a rotary microtome. Sections of about 5 μm in 
thickness were cut using rotary microtome (Model 82, American 
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Optical®, Oregon, USA), stained with hematoxylin, and counter-
stained with eosin (H&E) [16]. The slides were examined for 
Histopathological changes such as inflammatory reaction, necrosis, 
hemorrhagic areas and hyperkeratosis of the tumor by an observer 
who was blind with respect to the treatment groups. Tumors from 
groups B and C were excised just after animals’ death, stained 
using H&E stain and histopathologically examined using light 
microscope attached with camera (Leica, Germany).  
 
Results & discussion 
 
Niosomes entrapment efficiency 
 
5-FU is a hydrophilic drug so it can be efficiently solubilized in PBS 
(pH 7.4) and so it can be incorporated in the niosomal core. The 
obtained results showed that 5-FU has been successfully 
incorporated into niosomes core by an encapsulation efficiency 
reached up to 67.08 ± 2.53 % w/w (Table 2). It was obvious that 
Span 60 containing formulae had higher encapsulation efficiency 
compared to formulae containing Span 20. This can be attributed to 
the difference in alkyl chain length of surfactants. The alkyl chain of 
Span 60 is longer than that of Span 20 and it was reported that the 
longer the alkyl chain length the lower the permeability of the 
membrane and the higher the entrapment efficiency [17]. Sodium 
deoxycholate seemed to decrease the entrapment efficiency as it 
acts as a co-surfactant and increases the elasticity of the 
membrane and eventually decreases the entrapment efficiency 
[18]. It was noticed that increasing Span 60 increased the 
entrapment efficiency because the higher the amount of Span 60, 
the lower the permeability of the membrane and the higher the 
entrapment efficiency.  On the contrary, increasing Span 20 
decreased the entrapment efficiency as increasing Span 20 will 
decrease the rigidity of the membrane and finally decrease the 
entrapment efficiency.  
 
Zeta potential and particle size analysis 
 
Zeta potential values of niosomes ranged from -15 ± -1.6 to -37.73 
± -2.53 mV as can be seen in Table 2. Zeta potential values of 
Span 20 niosomes were higher than that of Span 60 niosomes this 
can be ascribed to the hydrophilic nature of Span 20. It was 
reported in literature that the more hydrophilic the surfactant, the 
higher the zeta potential values of vesicles [19]. Span 20 has an 
HLB value of 8.6 which is higher than that of Span 60 that is 4.7.  
Increasing amount of Span 20 increased zeta potential and the 
opposite was observed in case of Span 60 niosomes. 
Nadeoxycholate was noticed to zeta potential values.  
drug loaded niosomes had a particle size that ranged from 138 ± 
2.3 nm to 274 ± 1.99 nm with polydispersity index ranging from 
0.09 ± 0.06 to 0.2 ± 0.02 this indicates that most of the produced 
niosomes are somewhat monodispersed in the suspension which is 
a desirable property in such drug delivery system as it enhances 
stability and lessens the chance of aggregation of the formed 
particles. Span 60 containing niosomes were larger in size than 
niosomes containing Span 20. It is well established that the 
diameter of the vesicles depends on the surfactant’s alkyl chain 
length; consequently surfactants with longer alkyl chains generally 
give larger vesicles [20]. This could be the reason behind the 
smaller particle size of span 20 and larger particle size of Span 60 
niosomes. Increasing amount of Span 60 increased the particle 
size, while, increasing Span 20 amount decreased niosomes’ size.  
The co-surfactant Na deoxycholate seemed to decrease particle 
size. This decrease in particle size could be explained by increased 
flexibility and reduced surface tension of the vesicles induced by 
Nadeoxycholate [18]. 
 
Table 2: Zeta potential, particle size, polydispersity index and entrapment efficiency values of 5-FU loaded niosomes (mean ± SD)  
 
Formula No. Particle size (nm) Polydispersity index Zeta potential (mV) Entrapment 
Efficiency (% w/w) 
N1 211 ± 3.10 0.20 ± 0.02 -21.00 ± -1.40 52.65 ± 1.03 
N2 202 ± 2.00 0.19 ± 0.05 -24.66 ± -1.32 47.73 ± 2.17 
N3 274 ± 1.99 0.15 ± 0.03 -15.00 ± -0.99 67.08 ± 2.53 
N4 236 ± 3.90 0.16 ± 0.01 -17.00 ± -1.83 60.74 ± 4.00 
N5 169 ± 1.74 0.12 ± 0.02 -28.00 ± -1.00 51.06 ± 1.28 
N6 164 ± 1.50 0.13 ± 0.04 -31.00 ± -1.97 46.98 ± 1.63 
N7 143 ± 1.68 0.09 ± 0.06 -33.66 ± -1.20 40.05 ± 2.04 









Transmission electron microscopy 
 
Transmission electron micrographs illustrates that the formed 










                            
 
 Figure 1: Transmission electron photomicrographs of:  A) Span 20 niosomes and B): Span 60 niosomes.
In-vitro diffusion study 
 
From the results listed in Table (3) it’s clear that niosomal 
suspension increased the diffusion of 5-FU from all niosomes 
formulae compared to free 5-FU. Niosomes are composed of 
nonionic surfactants, which are biocompatible and relatively 
nontoxic and themselves serve as excellent penetration enhancers.
The niosomes as penetration enhancers may predominantly be on 
the intercellular lipids of stratum corneum raising the fluidity and 
weakness of stratum corneum resulting in increased penetration 
efficacy [21]. Also niosomal formulation as a lipid based drug 
delivery system may be able to penetrate through the lipophilic 
membranes like stratum corneum more efficiently than the 
hydrophilic 5-FU. It was worth noting that 5-FU loaded niosomes 
containing span 20 permeated more readily than those containing 
span 60 as a surfactant.  This difference can be attributed to 
smaller particle size of span 20 containing niosomes compared to 
larger particle size obtained in case of span 60 containing 
niosomes which in turn will increase the area available for diffusion. 
Also surfactants of lower Tc like span 20 (Tc =16oC) give more fluid 
membranes of the vesicles compared to surfactants having higher 
phase transition temperature like span 60 (Tc = 53
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oC) and hence 
 Increasing the amount of span 20 resulted in an improvement in 
diffusion parameters as noticed in formula N8 (composed of 150 
mg span 20, 55 mg cholesterol and 0.5% Na deoxycholate) which 
has permeation parameters considerably better than formula N6 
(composed of 100 mg span 20, 55 mg cholesterol and 0.5% Na 
deoxycholate). In the mean time increasing the concentration of 
span 60 seemed to decrease the permeation of niosomes. For 
example formula N1 (composed of 100 mg span 60, 45 mg 
cholesterol) had better permeation parameters than formula N3 
(composed of 150 mg span 60 along with 45 mg cholesterol). Na 
deoxycholate seemed to contribute to enhancement of 5
diffusion from niosomal formulae. In formula N7( containing 150 mg 
span 20, 55 mg cholesterol but no
permeation parameters were lower than those obtained with 
formula N8 that has same composition as N7 except that it contains 
Na deoxycholate. This increment in diffusion parameters in case of 
presence of Na deoxycholate can be referre
effect of Na deoxycholate which increases the flexibility of the 
membrane of niosomes and also gives smaller niosomes with 
larger surface area and greater area offered for diffusion. Figure (2) 
illustrated the permeation profiles of 
with the plain drug. 







 Na deoxycholate) the 
d to the co-surfactant 










































     Figure 2: Permeation profiles of 5
 
The in vitro diffusion studies of 5-FU gel formulae showed that 5
FU loaded niosomes’ gels had higher Q24 of 5-
formulae containing plain 5-FU due to their lipophilic nature so it 
can pass through lipophilic membranes adequately, this is in 
contrast to the hydrophilic 5- FU. Permeation parameters of 
different 5-FU gel formulae are shown in Table (4). Nevertheless; 
the amount of 5-FU diffused from 5-FU gel formulae were slightly 
smaller compared to those diffused from 5-FU niosomes, this could 
be explained by the hindrance to diffusion afforded by the viscous 
gel matrix   The highest values were observed in case of formula 
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-FU loaded niosomes formulae against free 5-FU (mean ± SD).
 (ug/cm2)a Lag time (min)b 
± 6.54 50.5 ± 2.98 
± 8.86 46.1 ± 3.10 
± 5.58 59.0 ± 1.99 
± 7.78 54.7 ± 2.00 
± 10.75 49.9 ± 3.20 
± 9.19 38.0 ± 2.70 
± 9.32 32.8 ± 3.50 
± 10.75 25.5 ±3.00 
± 4.00 80.0± 3.03 
-FU from 5-FU loaded niosomes along with free 5
-
FU than other 
composed of 5-FU loaded niosomes in NaCMC polymer, this can 
be attributed to repulsion between the negatively charged 
niosomes and the negative nucleus of the polymer. However it is 
also observed that drug diffused is some what gr
chitosan formula containing 5-FU than formula containing 5
loaded niosomes in chitosan, this might be due to repulsion 
between the acidic drug and the acidic chitosan gel, where as there 
could be some kind of attraction between the nega
niosomes and the acidic chitosan gel. Figure (3) illustrates diffusion 
profiles of 5-FU from different gel formulae.
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From the obtained data, the formula containing 5
niosomes respectively in NaCMC were chosen to perform the in 
vivo study against free 5-FU in the same matrix. 
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-FU loaded Stability study 
 
 It was observed from figure (4) that formula N8 exhibited a 
decrease in entrapment efficiency (EE) (% w/w) and increase in 
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particle size (nm) during the first three months of storage period. 
These changes were found to be insignificant using One
ANOVA. However, after six months of storage the decrease in 























Figure (5 B) shows that the tumors induced by EAC cells at the site 
of injection in the negative control slide was very prominent and 
showed fast growth in addition to sever hemorrhage and 
inflammatory reaction when compared with normal skin which show 
normal epidermal and dermal structure with no inflammatory 
reaction (Figure 5 A), these results come in agreement with what is 
reported in literature [22]. It was found that administration of free 5
FU as a topical preparation caused a little decrease the 
inflammatory reaction and hemorrhage induced by EAC as the 
slide is still showing clear hemorrhagic patches and inflammation 
(Figure 5 C).  
It was also found that topical application of 5-FU loaded niosomal 
gel (Figure 5 D) markedly decreased the inflammatory reactions 
and hemorrhagic patches previously noticed in negative control 












be significant. This means that up to three month of storage the 
prepared niosomes formula was somewhat stable however after six 
months of storage the formula was unstable concerning EE and 
particle size. 
-FU loaded niosomes (N8)  
-
deliver 5-FU more deeply compared to 5
improve the penetration of 5-FU into deeper layers of skin. These 
findings come in agreement with our in vitro diffusion studies which 
showed the efficiency of niosomes in delivering the hydrophili
therapeutic agent 5-FU to a higher extent than that of the 5
itself.  The significant reduction in the inflammatory reaction can be 
detected qualitatively under the microscope. 
related with the angiogenesis and growing facto
inflammation that are necessary for tumor development. The 
Ehrlich tumor implantation induces a local inflammatory reaction, 
with increasing vascular permeability, which results in an intense 
hemorrhagic areas formation, cellular migration an
ascetic fluid formation [23]. However, the niosomes loaded with the 
drug were able to reduce the inflammatory reaction, hyperkeratosis 
and were able to reduce the angiogenesis that is a feature of 
proliferation of new turmeric structure.
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Figure 5: Cross sections through A) Normal mouse skin, B)  Un treated skin tumor C) Skin tumor treated with free 5
with Niosomal 5-FU gel (at mag. Power 10x).  
Conclusion 
 
This study proved the ability of 5-FU to be incorporated in 
niosomes core with reasonable entrapment efficiency. The 
produced niosomes had particle size and zeta potential values that 
fall within the acceptable limits. All niosomes formulae had better 
diffusion compared to free drug. Gel matrix composed of NaCMC 









The Histopathological studies proved the greater ability of niosomal 
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